Mirataz™ is a transdermal ointment containing mirtazapine.  It is the first FDA-approved transdermal medication for the management of weight loss in cats. 

• In clinical studies, Mirataz resulted in significant weight gain in cats in as little as 14 days following topical application of 2mg per day
• Gives clients a practical way to manage their cat's weight loss without administration of oral medication and does not rely on the cat to eat to be medicated
• Mirataz achieves measurable plasma concentrations of mirtazapine in cats using proprietary Accusorb™ technology.
• Well tolerated both locally and systemically in clinical studies
• View the detailed product information for more detailed information and study reference